HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

From: US FDA; To: Supplement Industry – Tis The Season To Note Disease Claims, Undeclared Drugs

Executive Summary

FDA wraps end-of-year greetings to supplement industry about drug-spiked products labeled as supplements in a bow with officials sharing annual update of their oversight of the industry during a food and drug regulation gathering.

You may also be interested in...



Califf Returns To US FDA Helm As Familiar Consumer Health Regulation Problems Continue

Announcement of Senate confirmation of Robert Califf as commissioner came shortly after FDA announced recalls of products labeled as supplements but spiked with ED drugs. Like those and others recently identified as adulterated, supplements with undisclosed drugs were being found during Califf’s first stint in 2016 and 2017.

Amazon Testing Update Could, As FDA And Industry Want, Purge Bad Actors From Supplement Market

Latest update to Amazon’s screening policy for supplements requires showing sexual enhancement and weight loss products have been tested by third-party labs and lays out additional requirements for all supplement products.

US Fertility Supplement Marketers Don’t Deliver

FDA and FTC jointly warn five marketers of supplements with claims to treat fertility and other reproductive disorders. The unapproved and misbranded drugs could harm consumers and deter them from seeking effective treatments.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS152025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel